CTI Biopharma
Sobi/Apellis’ pegcetacoplan shows sustained efficacy in phase 3 kidney disease study
C3G and primary IC-MPGN are estimated to affect 5,000 people in the US and up to 8,000 in Europe
Sobi receives NICE recommendation for Altuvoct in severe haemophilia A
Approximately 7,700 people in England are living with the genetic bleeding disorder
Sobi receives MHRA approval for Altuvoct in severe or moderate haemophilia A
The factor VIII replacement therapy has been authorised to treat and prevent bleeding in children and adults
Sobi and Apellis’ pegcetacoplan shows promise in phase 3 rare kidney disease study
There are currently no treatments that target the underlying cause of C3G or IC-MPGN
Sanofi/Sobi’s haemophilia A therapy shows ‘highly effective’ bleed protection in children
The rare bleeding disorder affects approximately one in every 5,000 male births annually
Sobi receives EC marketing authorisation for Altuvoct in haemophilia A
The rare bleeding disorder affects approximately one in every 5,000 male births annually
Sanofi and Sobi’s Altuviiio label updated by FDA with expanded paediatric data in haemophilia A
The therapy’s weekly dosing has a half-life of up to four times longer than current factor VIII therapies
Sobi’s Aspaveli receives expanded EC approval for rare blood disorder PNH
The C3 therapy can now be used as a first-line treatment for paroxysmal nocturnal haemoglobinuria
Sanofi/Sobi’s efanesoctocog alfa recommended by CHMP to treat haemophilia A
The rare genetic condition reduces production of factor VIII, an essential protein for blood clotting
Sobi shares positive phase 3 results for Doptelet in paediatric patients with rare blood disorder ITP
Immune thrombocytopenia is estimated to affect up to 100 people per million
Novartis expands oncology pipeline with €2.7bn MorphoSys acquisition
The deal includes an investigational therapy being evaluated in myelofibrosis
GSK’s Omjjara approved by MHRA to treat myelofibrosis patients with anaemia
The rare blood cancer affects approximately one in every 500,000 people worldwide